In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. On Friday, Mad Money host Jim Cramer took a close look ...

We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a ...

We’ve got Eli Lilly that’s riding the wave of GLP-1 success…. Lilly’s last report laid an egg. They did it right on our show, unfortunately. I’m counting on this one being better ...

The request follows a similar move by Eli Lilly, which has asked for a ban on ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

Eli Lilly & Co. and Novo Nordisk A/S are competing for drug contracts in the aftermath of drug price scrutiny. Novo has managed to secure a contract with CVS, beating out its competitor. Other news is ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. The company is also ...

Cigna (CI) unveils ENGUIDE, a specialized GLP-1 pharmacy to be launched next month as demand for obesity drugs like Wegovy ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Eli Lilly and Company (NYSE: LLY) faced a sharp setback on Monday as HSBC issued a rare double downgrade, slashing its rating ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Thus, there are multiple reasons for Eli Lilly to stop sites from offering compounded versions of its GLP-1 drugs. They could not only help sales, but they can also help protect its brands.